IP Library Patent Application 16623525
Patent Application
App. No. 16/623,525

SLEEP DISORDER COMPOSITIONS AND TREATMENTS THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/623,525
Abstract

The invention relates to a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a cannabinoid fraction comprising Δ9-Tetrahydrocannabinol (THC), Cannabidiol (CBD), and Cannabinol (CBN) and a terpene fraction in an amount of at least 3% by weight of the extract. The invention also relates to methods of treating sleep disorders using this pharmaceutical composition.

Claims (16)

1 . A pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a cannabinoid fraction comprising Δ 9 -Tetrahydrocannabinol (THC), Cannabidiol (CBD), and Cannabinol (CBN) and a terpene fraction in an amount of at least 3% by weight of the extract.

2 . The pharmaceutical composition of claim 1 , comprising THC in an amount from 5% to 90% by weight of the extract.

3 . The pharmaceutical composition of claim 1 , comprising CBD in an amount from 1% to 20% by weight of the extract.

4 . The pharmaceutical composition of claim 1 , comprising CBN in an amount from 1% to 20% by weight of the extract.

5 . The pharmaceutical composition of claim 1 , wherein the terpene fraction comprises one or more of linalool, myrcene, and nerolidol.

6 . The pharmaceutical composition of claim 1 , wherein the terpene fraction comprises beta-myrcene in an amount from 1% to 50% by weight of the terpene fraction.

7 . The pharmaceutical composition of claim 1 , wherein the THC is a main cannabinoid.

8 . The pharmaceutical composition of claim 1 , wherein the ratio of THC:CBN is from 5:1 to 20:1.

9 . The pharmaceutical composition of claim 1 , wherein the ratio of THC:CBD is from 10:1 to 50:1.

10 . The pharmaceutical composition of claim 1 , wherein the Cannabis extract is a Cannabis oil.

11 . The pharmaceutical composition of claim 1 , the Cannabis extract comprises the terpene fraction in an amount of less than 50% by weight of the extract.

12 . The pharmaceutical composition of claim 1 , wherein the ratio of the cannabinoid fraction:terpene fraction is about 8:1 to about 33:1.

13 . (canceled)

14 . A medicament comprising an effective amount of the pharmaceutical composition of claim 1 .

15 . A method for treating a sleep disorder, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition of claim 1 .

16 . (canceled)

Assignments (2)
CHANGE OF NAME Recorded Nov 10, 2022
From: ZELDA THERAPEUTICS OPERATIONS PTY LTD
To: ZELIRA THERAPEUTICS OPERATIONS PTY LTD
Reel/Frame 061723/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2020
From: GORDON, MARA; SMITH, STEWART; WASHER, STEWART; WASHER, PATRIZIA; KARELIS, HARRY
To: ZELDA THERAPEUTICS OPERATIONS PTY LTD
Reel/Frame 052625/0955 →